Patents by Inventor Mohamed Iqbal
Mohamed Iqbal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11390792Abstract: A fluid composition including a base fluid; and an additive composition. The additive composition includes an emulsifier; a fluid loss control agent; a rheology modifier; and a viscosifier. The fluid composition is free or substantially free of organophilic clay. The fluid composition may be used as a drilling composition.Type: GrantFiled: November 16, 2018Date of Patent: July 19, 2022Assignee: OREN HYDROCARBONS LLCInventors: Mahaboob Subhahani Mohamed Ali, Mohamed Iqbal Batcha Imam Jafar Khan, Arivudainambi Udaiyar Shanmugavel Ezhil, Senthilkumar Sudararaj, Rizwan Ahmad
-
Patent number: 10874753Abstract: This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.Type: GrantFiled: September 25, 2015Date of Patent: December 29, 2020Assignees: The South African Nuclear Energy Corporation Limited, University of Cape TownInventors: Cathryn Helena Stanford Driver, Jan Rijn Zeevaart, Mohamed Iqbal Parker, Roger Hunter
-
Publication number: 20200283674Abstract: A fluid composition including a base fluid; and an additive composition. The additive composition includes an emulsifier; a fluid loss control agent: a rheology modifier; and a viscosifier. The fluid composition is free or substantially free of organophilic clay. The fluid composition may be used as a drilling composition.Type: ApplicationFiled: November 16, 2018Publication date: September 10, 2020Applicant: OREN HYDROCARBONS LLCInventors: Mahaboob Subhahani Mohamed ALI, Mohamed Iqbal Batcha Imam Jafar KHAN, Arivudainambi Udaiyar Shanmugavel EZHIL, Senthilkumar SUDARARAJ, Rizwan AHMAD
-
Publication number: 20170296684Abstract: This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.Type: ApplicationFiled: September 25, 2015Publication date: October 19, 2017Inventors: Cathryn Helena Stanford DRIVER, Jan Rijn ZEEVAART, Mohamed Iqbal PARKER, Roger HUNTER
-
Patent number: 9233115Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: GrantFiled: July 24, 2013Date of Patent: January 12, 2016Assignee: Millennium Pharmaceuticals Inc.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Publication number: 20140088042Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: ApplicationFiled: July 24, 2013Publication date: March 27, 2014Applicant: Cephalon, Inc.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Patent number: 8546608Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: GrantFiled: September 30, 2011Date of Patent: October 1, 2013Assignee: Cephalon, Inc.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Patent number: 8524781Abstract: Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1-C5 alkyl; linear or branched C1-C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched C1-C5 alkenyl or substituted linear or branched C1-C5 alkyl, in which the substituents are selected from OR3, NR4R5, COOR6, CON—R7R8, in which R3 is selected from H, COR9, para-methoxybenzyl and trialkylsilyl, in which R9 is alkyl or substituted alkyl; R4 N and R5 are alkyl or R4 and R5 together form a phthalimido group; R6 is alkyl or substituted alkyl; and R7 and R8 are alkyl or substituted alkyl; substituted or unsubstituted aromatic specifically where R1 and R2 are benzyl, para-methoxybenzyl and/or ortho,para-methoxybenzyl and substituted or unsubstituted heteroaromatic. The compounds can be used for inhibiting the growth of tumor cells and for treating cancer. A pharmaceutical composition and a method of preparing the compounds are also described.Type: GrantFiled: August 5, 2009Date of Patent: September 3, 2013Assignee: University of Cape TownInventors: Catherine Hart Kaschula, Roger Hunter, Mohamed Iqbal Parker
-
Patent number: 8314155Abstract: The present invention provides compounds of the structure: wherein the constituent members are defined herein, including pharmaceutical compositions thereof and methods of treating diseases therewith.Type: GrantFiled: June 20, 2008Date of Patent: November 20, 2012Assignees: Cephalon, Inc, Cephalon FranceInventors: Edward R. Bacon, Sankar Chatterjee, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet
-
Publication number: 20120041196Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: ApplicationFiled: September 30, 2011Publication date: February 16, 2012Applicant: CEPHALON, INC.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassará, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Patent number: 8058262Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: GrantFiled: February 3, 2011Date of Patent: November 15, 2011Assignee: Cephalon, Inc.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Publication number: 20110190368Abstract: Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1-C5 alkyl; linear or branched C1-C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched C1-C5 alkenyl or substituted linear or branched C1-C5 alkyl, in which the substituents are selected from OR3, NR4R5, COOR6, CON—R7R8, in which R3 is selected from H, COR9, para-methoxybenzyl and trialkylsilyl, in which R9 is alkyl or substituted alkyl; R4 N and R5 are alkyl or R4 and R5 together form a phthalimido group; R6 is alkyl or substituted alkyl; and R7 and R8 are alkyl or substituted alkyl; substituted or unsubstituted aromatic specifically where R1 and R2 are benzyl, para-methoxybenzyl and/or ortho,para-methoxybenzyl and substituted or unsubstituted heteroaromatic. The compounds can be used for inhibiting the growth of tumour cells and for treating cancer. A pharmaceutical composition and a method of preparing the compounds are also described.Type: ApplicationFiled: August 5, 2009Publication date: August 4, 2011Applicant: University of Cape TownInventors: Catherine Hart Kaschula, Roger Hunter, Mohamed Iqbal Parker
-
Patent number: 7981907Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.Type: GrantFiled: August 27, 2008Date of Patent: July 19, 2011Assignees: Cephalon, Inc., Cephalon FranceInventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Marie-Edith Gourdel, Greg Hostetler, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet, Eric Riguet, Dominique Schweizer, Christophe Yue
-
Publication number: 20110144033Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: ApplicationFiled: February 3, 2011Publication date: June 16, 2011Applicant: CEPHALON, INC.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Patent number: 7915236Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: GrantFiled: July 1, 2009Date of Patent: March 29, 2011Assignee: Cephalon, Inc.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Publication number: 20090291918Abstract: The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.Type: ApplicationFiled: July 1, 2009Publication date: November 26, 2009Applicant: Cephalon, Inc.Inventors: Raffaella Bernardini, Alberto Bernareggi, Paolo G. Cassara, Sankar Chatterjee, Germano D'Arasmo, Sergio De Munari, Edmondo Ferretti, Mohamed Iqbal, Ernesto Menta, Patricia A. Messina McLaughlin, Ambrogio Oliva
-
Patent number: 7546996Abstract: A device is provided for securing a writing tablet to a frame member. The tablet defines first and second opposing lateral edges. The device comprises an elongate bar, a clamp member, and first and second support elements. The elongate bar defines a distal end. The clamp member is attached to the distal end of the bar and is fastenable to the frame member. The first and second support elements are attached to the bar and are positionable along a length of the bar. The support elements each include an engagement surface configured to engage the first and second lateral edges of the tablet.Type: GrantFiled: August 30, 2005Date of Patent: June 16, 2009Inventor: Mohamed Iqbal Somji
-
Publication number: 20090062284Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl acetamides of Formula (I): wherein Ar, Y, R1, R2, R4, R5, q and x are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness associated with narcolepsy, obstructive sleep apnea, or shift work disorder; Parkinson's disease; Alzheimer's disease; attention deficit disorder; attention deficit hyperactivity disorder; depression; or fatigue associated with a neurological disease; as well as the promotion of wakefulness.Type: ApplicationFiled: August 27, 2008Publication date: March 5, 2009Applicant: Cephalon, Inc.Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, Marie-Edith Gourdel, Greg A. Hostetler, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet, Eric Riguet, Dominique Schweizer, Christophe Yue
-
Publication number: 20090042907Abstract: The present invention provides compounds of the structure: wherein the constituent members are defined herein, including pharmaceutical compositions thereof and methods of treating diseases therewith.Type: ApplicationFiled: June 20, 2008Publication date: February 12, 2009Applicants: Cephalon, Inc., Cephalon FranceInventors: Edward R. Bacon, Sankar Chatterjee, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet
-
Patent number: D914480Type: GrantFiled: February 20, 2019Date of Patent: March 30, 2021Assignee: IGLOOHOME PTE. LTDInventors: Kai Hui Tan, Chun Chiang Chan, Mathew Mantik Ng, Nur Yani Binte Mohamed Iqbal